Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-1201 in Advanced Solid Tumors
NCT04866641Phase 1Recruiting
- Sponsor
- Taivex Therapeutics
- Start
- Jun 2021
- Primary completion
- Nov 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of T-1201 in solid tumor (advanced stage), sponsored by Taivex Therapeutics. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
T-1201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04866641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866641.